CEL-SCI Acquired by Amarox | Healthcare M&A Deal

Amarox has completed the acquisition of CEL-SCI, a pharmacy business in Virginia, for $2.7 billion. CEL-SCI develops Multikine (leukocyte interleukin injection) for head and neck cancer, and the Amarox partnership focuses on Saudi Arabia regulatory affairs, commercialization, and distribution. Amarox will act as local regulatory representative with the Saudi Food and Drug Authority (SFDA) to pursue Breakthrough Medicine Designation and enable faster patient access in Saudi Arabia. The strategic acquisition is structured as a 50%/50% net revenue sharing agreement for Multikine sales, with Amarox receiving exclusive distribution rights upon SFDA approval and optional expansion to GCC countries.